- Molecular NameCyproterone
- SynonymCyproterone acetate
- Weight374.908
- Drugbank_IDDB04839
- ACS_NO2098-66-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.16
- pkaN/A
- LogD (pH=7, predicted)3.16
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.83
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds1
- TPSA54.37
- StatusFDA approved
- AdministrationOral, intramuscular
- PharmacologyAn antiandrogen, i.e. it suppresses the actions of testosterone (and its metabolite dihydrotestosterone) on tissues. It acts by blocking androgen receptors which prevents androgens from binding to them and suppresses luteinizing hormone (which in turn reduces testosterone levels). Its main indications are prostate cancer, benign prostatic hyperplasia, priapism, hypersexuality and other conditions in which androgen action maintains the disease process. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgender people.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability100.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life40 h
- Excretion60% bile, 33% renal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A